| Changes in the expression and function of the PDE5 pathway in the obstructed urinary bladder. | Changes in the expression and function of the PDE5 pathway in the obstructed urinary bladder.
He W, Xiang H, Liu D, Liu J, Li M, Wang Q, Qian Q, Li Y, Fu X, Chen P, Guo Y, Zeng G, Wu Z, Zhan D, Wang X, DiSanto ME, Zhang X., Free PMC Article | 06/26/2021 |
| Differential expression of caveolin-1 during pathogenesis of combined pulmonary fibrosis and emphysema: Effect of phosphodiesterase-5 inhibitor. | Differential expression of caveolin-1 during pathogenesis of combined pulmonary fibrosis and emphysema: Effect of phosphodiesterase-5 inhibitor.
Kulshrestha R, Singh H, Pandey A, Soundarya D, Jaggi AS, Ravi K. | 01/9/2021 |
| Our data showed a significant and previously undocumented upregulation of PDE5 in both rat and human BPH. | Upregulation of Phosphodiesterase type 5 in the Hyperplastic Prostate.
Zhang W, Zang N, Jiang Y, Chen P, Wang X, Zhang X., Free PMC Article | 10/22/2016 |
| The effects of vasodilation on plasma volume expansionhemodilution, and PDE5A expression via the renin-angiotensin-aldosterone system are reported. | Chronic vasodilation increases renal medullary PDE5A and α-ENaC through independent renin-angiotensin-aldosterone system pathways.
West CA, Shaw S, Sasser JM, Fekete A, Alexander T, Cunningham MW Jr, Masilamani SM, Baylis C., Free PMC Article | 01/25/2014 |
| The phosphodiesterase 5A inhibitors decrease NHE-1 phosphorylation and activity through a mechanism that involves PP2A activation. | Phosphodiesterase 5A inhibition decreases NHE-1 activity without altering steady state pH(i): role of phosphatases.
Díaz RG, Nolly MB, Massarutti C, Casarini MJ, Garciarena CD, Ennis IL, Cingolani HE, Pérez NG. | 03/5/2011 |
| increased expressions of PKG I and StAR complex, accompanied by decreased PDE5 activity, suggest that NO-cGMP signalling pathway and consequent activation of StAR protein regulate the adaptive response of Leydig cells to repeated immobilization stress. | Structural complexity of the testis and PKG I / StAR interaction regulate the Leydig cell adaptive response to repeated immobilization stress.
Kostic TS, Stojkov NJ, Janjic MM, Andric SA. | 01/1/2011 |
| PDE5-inhibition blocks TRPC6 channel activation and associated Cn/NFAT activation signaling by PKG-dependent channel phosphorylation | Cyclic GMP/PKG-dependent inhibition of TRPC6 channel activity and expression negatively regulates cardiomyocyte NFAT activation Novel mechanism of cardiac stress modulation by PDE5 inhibition.
Koitabashi N, Aiba T, Hesketh GG, Rowell J, Zhang M, Takimoto E, Tomaselli GF, Kass DA., Free PMC Article | 11/27/2010 |
| phosphorylation and functional suppression of TRPC6 underlie prevention of pathological hypertrophy by PDE5 inhibition. | Phosphorylation of TRPC6 channels at Thr69 is required for anti-hypertrophic effects of phosphodiesterase 5 inhibition.
Nishida M, Watanabe K, Sato Y, Nakaya M, Kitajima N, Ide T, Inoue R, Kurose H., Free PMC Article | 05/31/2010 |
| PDE5 expression was not under direct androgen regulation. | Lack of direct androgen regulation of PDE5 expression.
Yang R, Huang YC, Lin G, Wang G, Hung S, Dai YT, Sun ZY, Lue TF, Lin CS., Free PMC Article | 01/21/2010 |
| Phosphodiesterase 5A expression confirms the activity targeted inhibition by sildenafil in cardiomyocytes and hypertrophy modulation. | Expression, activity, and pro-hypertrophic effects of PDE5A in cardiac myocytes.
Zhang M, Koitabashi N, Nagayama T, Rambaran R, Feng N, Takimoto E, Koenke T, O'Rourke B, Champion HC, Crow MT, Kass DA., Free PMC Article | 01/21/2010 |
| sildenafil activates a PKG-dependent novel signaling cascade that involves activation of ERK and inhibition of glycogen synthase kinase 3beta leading to cytoprotection | Protein kinase G-dependent cardioprotective mechanism of phosphodiesterase-5 inhibition involves phosphorylation of ERK and GSK3beta.
Das A, Xi L, Kukreja RC., Free PMC Article | 01/21/2010 |
| PDE5 activity limits action potential propagation in neurohypophysial axons. | Blockade of phosphodiesterase Type 5 enhances rat neurohypophysial excitability and electrically evoked oxytocin release.
Zhang Z, Klyachko V, Jackson MB., Free PMC Article | 01/21/2010 |
| Kinetics of rat cellular nitric oxide/cGMP/phosphodiesterase-5 pathway | Kinetics of a cellular nitric oxide/cGMP/phosphodiesterase-5 pathway.
Mo E, Amin H, Bianco IH, Garthwaite J. | 01/21/2010 |
| PDE5 controls the soluble cyclic GMP pool in cardiac myocytes. | Cyclic guanosine monophosphate compartmentation in rat cardiac myocytes.
Castro LR, Verde I, Cooper DM, Fischmeister R., Free PMC Article | 01/21/2010 |
| normal rat pregnancy leads to in vivo and in vitro renal resistance to atrial natriuretic peptide, in association with heightened activity of the cGMP-specific PDE5 | Increased activity of cGMP-specific phosphodiesterase (PDE5) contributes to resistance to atrial natriuretic peptide natriuresis in the pregnant rat.
Ni XP, Safai M, Rishi R, Baylis C, Humphreys MH., Free PMC Article | 01/21/2010 |
| PDE-5 is constitutively present in the rat uterine wall. There was no observed change in the PDE-5 protein expression throughout pregnancy. | The presence and function of phosphodiesterase type 5 in the rat myometrium.
Buhimschi CS, Garfield RE, Weiner CP, Buhimschi IA. | 01/21/2010 |
| mRNA transcript and protein levels of PDE5 in the main and first branch of the pulmonary arteries are increased by chronic hypoxia. | Increased expression of the cGMP-inhibited cAMP-specific (PDE3) and cGMP binding cGMP-specific (PDE5) phosphodiesterases in models of pulmonary hypertension.
Murray F, MacLean MR, Pyne NJ., Free PMC Article | 01/21/2010 |
| Increased PDE-5 expression is involved in the decreased vascular response to nitric oxide in cirrhotic livers | Increased phosphodiesterase-5 expression is involved in the decreased vasodilator response to nitric oxide in cirrhotic rat livers.
Loureiro-Silva MR, Iwakiri Y, Abraldes JG, Haq O, Groszmann RJ. | 01/21/2010 |
| PDE5A may also play a critical role in the growth promoting effects of Angiotensin II | Angiotensin II increases phosphodiesterase 5A expression in vascular smooth muscle cells: a mechanism by which angiotensin II antagonizes cGMP signaling.
Kim D, Aizawa T, Wei H, Pi X, Rybalkin SD, Berk BC, Yan C., Free PMC Article | 01/21/2010 |